Protocol Ledger

NCT06337318 · Phase III · RECRUITING

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

Interventional Phase III clinical trial protocol NCT06337318 sponsored by National Cancer Institute (NCI) in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-10-23 Enrollment: 600 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06337318
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)600 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06337318
Protocol FieldVerified Registry Value
NCT IdentifierNCT06337318
Consolidated Lead SponsorNational Cancer Institute (NCI)
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment600 participants (ESTIMATED)
Registered Start Date2024-10-23
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI